此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

HFpEF 患者右侧内脏大神经的血管内消融术 (Rebalance-HF)

2026年9月16日 更新者:Axon Therapies, Inc.

右大内脏神经的血管内消融术在患有 HFpEF 的受试者中右大内脏神经的血管内消融术:可行性研究:随机对照可行性试验 - 再平衡 HF 研究

The purpose of this clinical study is to evaluate the safety and early effectiveness of a catheter-based procedure that treats a nerve called the right greater splanchnic nerve. The study includes people who have heart failure with preserved ejection fraction (HFpEF). The goal is to learn whether this procedure, performed using the Satera Ablation System, may help improve symptoms and to better understand which patients may benefit most from this treatment in the future.

研究概览

详细说明

Up to 150 people will take part in this clinical study.

Phase I of the REBALANCE-HF Study

The first part of the study took place between January 2021 and March 2023. During this phase, 116 patients participated. Researchers reviewed the results to learn whether the procedure appeared safe and whether it might help improve symptoms in people with heart failure with preserved ejection fraction (HFpEF).

This early review showed encouraging results in some patients. It also helped researchers identify a group of patients who seemed more likely to benefit from the procedure.

Phase II of the REBALANCE-HF Study:

The current phase of the study focuses on patients who have similar characteristics to those who responded well in Phase I. The goal is to confirm whether this group of patients may benefit most from the treatment and whether the procedure should be studied further in a larger future trial.

This study will take place at multiple hospitals and research centers.

Participants who qualify for the study will be randomly assigned to one of two groups:

  • Treatment group: The procedure is performed using the Satera Ablation System to treat a nerve called the greater splanchnic nerve.
  • Control (sham) group: A simulated procedure is performed, but the treatment itself is not delivered.

Participants will be assigned to a group by chance, similar to flipping a coin, although twice as many patients will receive the treatment as the sham procedure (2:1 ratio).

The group assignment will happen during the procedure after anesthesia is given, and only after the doctor confirms that the patient's anatomy is suitable for the procedure.

Blinding:

To make sure the results are fair and unbiased:

  • Participants and their heart failure doctors will not know whether the patient received the treatment or the sham procedure.
  • The doctor performing the procedure and certain study staff will know which procedure is performed so they can carry out the procedure safely.
  • The study safety team will also know this information to help monitor patient safety.

Sham Procedure:

A sham procedure is used to help researchers understand whether any improvements are due to the treatment itself or to the placebo effect.

During the sham procedure:

A small needle puncture is made in the groin or neck, similar to what is done for many heart procedures.

Doctors check the veins to confirm whether the procedure could have been performed.

However, the treatment catheter is not used and the nerve is not treated.

The sham procedure takes about 45 minutes, which is about the same amount of time as the treatment procedure.

Number of Participants:

90 patients were assigned to treatment or sham during Phase I.

In Phase II, up to 60 additional patients will be enrolled.

About 40 patients will receive the treatment, and about 20 will receive the sham procedure.

研究类型

介入性

注册 (估计的)

150

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Tbilisi、乔治亚州
        • 招聘中
        • Tbilisi Heart and Vascular Center
        • 首席研究员:
          • Tamaz Shaburishvili, MD
        • 接触:
      • Tbilisi、乔治亚州
        • 主动,不招人
        • Tbilisi Heart Center
    • Alabama
      • Birmingham、Alabama、美国、35211
        • 完全的
        • Cardiology PC
    • Arizona
      • Phoenix、Arizona、美国、85016
        • 完全的
        • Arizona Cardiovascular Research Center
    • California
      • La Jolla、California、美国、92037
        • 招聘中
        • Scripps Health
        • 首席研究员:
          • Rajeev Mohan, MD
        • 首席研究员:
          • Matthew Price, MD
        • 接触:
      • San Francisco、California、美国、94143
        • 招聘中
        • University of California, San Francisco
        • 首席研究员:
          • Liviu Klein, MD
        • 接触:
      • San Francisco、California、美国、94143
        • 招聘中
        • Zuckerberg San Francisco General Hospital and Trauma Center
        • 接触:
        • 首席研究员:
          • Lucas ZIer, MD
    • Georgia
      • Augusta、Georgia、美国、30901
    • Illinois
      • Chicago、Illinois、美国、60611
        • 招聘中
        • Bluhm Cardiovascular Institute of Northwestern University
        • 首席研究员:
          • Ravi Patel, MD
        • 接触:
      • Chicago、Illinois、美国、60637
      • Springfield、Illinois、美国、62701
        • 完全的
        • Prairie Education and Research Cooperative
    • Indiana
      • Indianapolis、Indiana、美国、46260
        • 完全的
        • Ascension St. Vincent - Cardiovascular Research Institute
    • Louisiana
      • Houma、Louisiana、美国、70360
        • 招聘中
        • Cardiovascular Institute of the South
        • 首席研究员:
          • Peter Fail, MD
        • 接触:
    • Michigan
      • Ann Arbor、Michigan、美国、48109
        • 招聘中
        • Michigan Medicine, University of Michigan
        • 首席研究员:
          • Scott Hummel, MD
        • 接触:
    • Minnesota
      • Rochester、Minnesota、美国、55905
        • 招聘中
        • Mayo Clinic
        • 首席研究员:
          • Barry Borlaug, MD
        • 接触:
    • Missouri
      • St Louis、Missouri、美国、63136
        • 招聘中
        • St. Louis Heart and Vascular
        • 首席研究员:
          • Gil Vardi, MD
        • 接触:
    • New York
      • New York、New York、美国、10021
        • 招聘中
        • Weill Cornell Medicine
        • 首席研究员:
          • Parag Goyal, MD
        • 接触:
      • New York、New York、美国、10032
        • 招聘中
        • Columbia University Medical Center
        • 首席研究员:
          • Nir Uriel, MD
        • 接触:
      • New York、New York、美国、10029
        • 完全的
        • Icahn School of Medicine at Mount Sinai
      • Rochester、New York、美国、14621
    • North Carolina
      • Durham、North Carolina、美国、27710
        • 招聘中
        • Duke University Medical Center
        • 首席研究员:
          • Marat Fudim, MD, MHS
        • 接触:
    • Ohio
      • Cincinnati、Ohio、美国、45219
      • Columbus、Ohio、美国、43210
        • 招聘中
        • Ohio State University Wexner Medical Center
        • 首席研究员:
          • Alexandria Miller, MD
        • 接触:
    • South Carolina
      • Charleston、South Carolina、美国、29425
        • 招聘中
        • Medical University of South Carolina
        • 首席研究员:
          • Sheldon Litwin, MD
        • 接触:
    • Texas
      • Houston、Texas、美国、77030
        • 招聘中
        • Baylor College of Medicine
        • 首席研究员:
          • Ajith Nair, MD
        • 接触:
    • Virginia
      • Richmond、Virginia、美国、23298
        • 完全的
        • Virginia Commonwealth University Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

40年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria

  1. Chronic heart failure, defined as:

    1. Symptoms of HF requiring current (intermittent or continuous) treatment with diuretics for >30 days, AND
    2. NYHA class II with a history of >NYHA class II in the past year, NYHA class III, or ambulatory NYHA class IV symptoms (paroxysmal nocturnal dyspnea, orthopnea, dyspnea on mild or moderate exertion) at screening or signs of HF (any rales post cough, chest x-ray demonstrating pulmonary congestion), AND
    3. At least one of the following:

    i. ≥1 HF hospital admission (with HF as the primary diagnosis) including treatment with intravenous (IV) diuretics or urgent unplanned treatment with IV diuretics in healthcare facility within past 12 months, OR ii. NT-proBNP >300 pg/ml in normal sinus rhythm (>450 pg/ml in atrial fibrillation or flutter) within the past 6 months; BNP >100 pg/ml in normal sinus rhythm (>300 pg/ml in atrial fibrillation or flutter) within the past 6 months, OR iii. Right heart catheterization (RHC) with PCWP ≥ with PCWP ≥18 mmHg at rest or 25 mmHg during exercise at the time of the screening RHC.

  2. Ongoing stable GDMT HF management (unless unable to tolerate GDMT) and management of potential comorbidities according to the 2022 ACCF/AHA Guideline for the Management of Heart Failure (Class 1 and 2a recommendations), with no significant changes [≥100% increase or ≥50% decrease] for a minimum of 1 month (30 days) prior to screening, that is expected to be maintained without change for at least 6 months. Participants cannot have started a glucagon-like peptide (GLP)-1 or gastric inhibitory peptide (GIP) agonist within the last 6 months or plan to start a GLP-1 or GIP agonist within the ensuing 6 months after enrollment.

  3. LVEF ≥50% (site-determined by transthoracic echocardiography) within the past 6 months.

  4. Age ≥40 years.

  5. Subject is willing and able to provide appropriate study-specific informed consent, follow protocol procedures, and comply with follow-up visit requirements.

Exclusion Criteria:

  1. MI (type I) and/or percutaneous cardiac intervention within 3 months prior to screening; CABG in past 3 months prior to screening, or current indication for coronary revascularization.

  2. Cardiac resynchronization therapy initiated within 3 months prior to screening.

  3. Advanced heart failure defined as one or more of the following:

    1. ACC/AHA/ESC Stage D HF or non-ambulatory NYHA Class IV HF.
    2. Inotropic infusion (continuous or intermittent) within 6 months prior to screening.
    3. Subject is on the cardiac transplant waiting list.
    4. Presence of or prior history of mechanical circulatory support for HF.
  4. Poor left heart compliance as determined by pulse-wave Doppler transmitral early-to-late (E/A) ratio >2.0 assessed by the screening echocardiogram. The Screening Committee will evaluate left heart function if the transmitral A velocity is not measurable or absent.

  5. Right heart dysfunction defined as tricuspid annular plane systolic excursion (TAPSE) <12 mm or right ventricular (RV) fractional area change (FAC) <25% assessed by the screening echocardiogram.

  6. Body mass index (BMI) >45 kg/m2.

  7. 6-minute walk test distance <100 meters OR >450 meters.

  8. Admission for HF within the 30 days prior to planned index procedure.

  9. Any known history of orthostatic hypotension or orthostatic hypotension at the time of screening (regardless of the presence of symptoms). Orthostatic hypotension is defined as a systolic blood pressure (BP) decrease of >20 mmHg upon going from supine to standing position or undergoing treatment with Midodrine.

  10. Orthostatic pulse pressure change from supine to standing decrease of >10mmHg in the absence of a HR increase >15bpm

  11. Postural orthostatic tachycardia syndrome or preload insufficiency syndrome.

  12. Systolic BP <100 mmHg or >170 mmHg despite appropriate medical management.

  13. Baseline screening ECG resting HR >100 beats per minute or ventricular tachycardia.

  14. Catheter ablation for atrial fibrillation within 6 months prior to screening or planned in the next 12 months at the time of screening.

  15. Left ventricular EF <40% within the 3 years prior to screening unless reduced EF was transient and associated with an acute event.

  16. Presence of significant valve disease defined by the site cardiologist as:

    1. Greater than mild mitral valve stenosis.
    2. Greater than moderate mitral valve regurgitation.
    3. Greater than moderate-to-severe tricuspid valve regurgitation.
    4. Greater than moderate aortic valve stenosis or regurgitation.
  17. Known hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, cardiac amyloidosis, or other infiltrative cardiomyopathy (e.g., hemochromatosis, sarcoidosis).

  18. History of clinically significant liver cirrhosis.

  19. Prior weight loss surgery

  20. Dialysis dependent; or estimated GFR <25 ml/min/1.73 m2 by CKD-EPI creatinine equation.

  21. Arterial oxygen saturation <90% on room air.

  22. Chronic pulmonary disease requiring continuous home oxygen OR hospitalization for exacerbation of chronic pulmonary disease (including intubation) in the 12 months before study entry OR known history of GOLD Class III or worse chronic obstructive pulmonary disease (COPD).

  23. Participating in conflicting investigational drug or device study that is not completed within 30 days prior to the screening visit.

  24. Life expectancy <12 months for non-cardiovascular reasons.

  25. Any condition, or history of illness or surgery that, in the opinion of the site investigator or Screening Committee, might confound the results of the study or pose additional risks to the patient.

  26. Females who are pregnant or lactating or planning to become pregnant during the next year.

  27. Any of the following measured by screening right heart catheterization:

    1. Mean right atrial pressure (RAP) >20 mmHg at rest
    2. Cardiac index <2.0 L/min/m2 at rest
    3. Pulmonary vascular resistance (PVR) >4 Wood units

    Exclusion Criteria Assessed During the index procedure:

  28. Vessel tortuosity or variant vascular anatomy that could preclude the access or maneuvering of the interventional device from the access site to target vessel. This includes previous spine surgery that may impact the ability to access and treat the target sites of T11 and T10.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
有源比较器:Greater Splanchnic Nerve Ablation

After anesthesia is given, doctors will use the Satera Ablation System to reach a nerve called the right greater splanchnic nerve. Subjects receive catheter-based unilateral ablation of the right greater splanchnic nerve.

The greater splanchnic nerve (GSN) ablation procedure begins with a small needle puncture in the groin or neck to access a vein, using methods that are commonly used for heart procedures. Doctors then guide thin tubes and wires through the vein to reach a nerve called the right greater splanchnic nerve. X-ray imaging is used to help the doctor see where the catheter is and guide it to the correct location. Once the catheter is in the right place, the doctor uses the device to treat the nerve using controlled heat.

假比较器:Sham Control Arm

After anesthesia is given, doctors will place a small tube into a vein. The steps and length of the procedure will be similar to the Axon treatment procedure, but the study treatment will not be performed.

During the sham procedure, a small needle puncture will be made in the groin or neck to access a vein using standard medical techniques. A short tube will be placed into the vein, similar to what is done for many heart procedures. The Satera catheter and treatment devices will not be inserted, and the nerve will not be treated. The procedure will take about the same amount of time as the treatment procedure.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Primary Safety Endpoint: Device or procedure related serious adverse events
大体时间:1 Month

Evaluation of device or procedure-related serious adverse events at 1-month follow-up based on Clinical Events Committee (CEC) assessment

1 Month
Primary Efficacy Endpoint: KCCQ (6 months)
大体时间:Baseline through 6-months

Assessment of change in Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline to 6-month follow up visit

Baseline through 6-months
Primary Efficacy Endpoint: 6MWT (6 months)
大体时间:Baseline through 6 months

Assessment of change in Six Minute Walk Test (6MWT) from baseline to the 6-month follow up visit

Baseline through 6 months

次要结果测量

结果测量
措施说明
大体时间
Pulmonary Capillary Wedge Pressure (PCWP)
大体时间:Baseline through 1-month

Change in pulmonary capillary wedge pressure (PCWP) at resting, legs up, 20 Watts, and Peak Exercise Stage from Baseline to the 1-month follow up visit

Baseline through 1-month
Stress blood volume
大体时间:Baseline through 1-month

Change in estimated stress blood volume at resting, legs up, 20Watts, and Peak Exercise Stage from Baseline to the 1-month follow up visit.

Baseline through 1-month
NT-proBNP
大体时间:Baseline through 24-months

Change in NT-proBNP levels from Baseline through the 24-month visit

Baseline through 24-months
KCCQ (24-months)
大体时间:Baseline through 24-months

Change in KCCQ scores from baseline through the 24-month visit

Baseline through 24-months
6MWT (24-months)
大体时间:Baseline through 24-months

Change in 6MWT from Baseline through the 24-month visit

Baseline through 24-months
Time to first heart failure event
大体时间:Treatment through 24-months

Time to first heart failure event (hospitalizations and worsening heart failure events) through the 24-month visit

Treatment through 24-months
Incidence of heart failure events
大体时间:Treatment through 24-months

Incidence of heart failure events (hospitalizations and worsening heart failure events) through the 24-month visit

Treatment through 24-months
Hierarchical composite endpoint (12-months)
大体时间:Baseline through 12-months

Composite endpoint of cardiovascular death, heart failure events, and changes in KCCQ from Baseline to the 12-month visit

Baseline through 12-months
Incidence of serious device related cardiac or vascular events
大体时间:Treatment through 12- and 24-months

Assessment of the incidence of serious device related cardiac or vascular events through 12- and 24-months

Treatment through 12- and 24-months
Device or procedure related pain
大体时间:Treatment through 24-months

Assessment of device or procedure related pain lasting at least 30 days and requiring medical management

Treatment through 24-months
Orthostatic hypotension
大体时间:Treatment through 12- and 24-months

Incidence of new orthostatic hypotension up to 12- and 24-months

Treatment through 12- and 24-months
Acute Kidney Injury (AKI)
大体时间:Baseline through 12-and 24-months

Incidence of AKI requiring renal replacement therapy up to 12- and 24-months

Baseline through 12-and 24-months
Glomerular Filtration Rate (GFR)
大体时间:Baseline through 12- and 24-months

Incidence of worsening GFR (defined as >50% for at least 30 days in duration) up to 12- and 24-months

Baseline through 12- and 24-months
Adverse Events
大体时间:Procedure through 12- and 24-months

Incidence of all Adverse Events through 12- and 24-months

Procedure through 12- and 24-months
Mortality
大体时间:Procedure through 6-, 12- and 24-months

Incidence of all mortality for up to 6-, 12-, and 24-months summarized as all-cause mortality, CV mortality, or heart failure-related

Procedure through 6-, 12- and 24-months

其他结果措施

结果测量
措施说明
大体时间
Exploratory endpoint: Heart failure related medication changes (24-months)
大体时间:Baseline through 24-months

Freedom from heart failure related medication changes through the 24-month visit

Baseline through 24-months
Exploratory Endpoint: Diuretic medication (24-months)
大体时间:Baseline through 24-months

Change in diuretic dose through the 24-month visit

Baseline through 24-months
Exploratory Endpoint: Diastolic function (24-months)
大体时间:Baseline through 24-months

Assessment of diastolic function by transthoracic echocardiography evaluated over time from baseline through 24-months

Baseline through 24-months
Exploratory Endpoint: C-reactive protein
大体时间:Baseline through 24-months

Change in c-reactive protein levels from Baseline through 24-months

Baseline through 24-months
Exploratory Endpoint: Aldosterone (ALD)
大体时间:Baseline through 24-months

Change in aldosterone levels from Baseline through 24-months

Baseline through 24-months
Exploratory Endpoint: Renin
大体时间:Baseline through 24-months

Change in Renin levels from Baseline through 24-months

Baseline through 24-months
Exploratory Endpoint: Weight
大体时间:Baseline through 24-months

Change in weight from Baseline through 24-months

Baseline through 24-months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Sanjiv S Shah, MD、Northwestern University

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年12月18日

初级完成 (估计的)

2028年1月10日

研究完成 (估计的)

2029年8月10日

研究注册日期

首次提交

2020年10月7日

首先提交符合 QC 标准的

2020年10月13日

首次发布 (实际的)

2020年10月19日

研究记录更新

最后更新发布 (实际的)

2026年9月21日

上次提交的符合 QC 标准的更新

2026年9月16日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅